Program
Chlorhexidine
Also written as “chlorhexidine (CHX)”, “Chlorhexidine 2.5 mg” and “chlorhexidine/lidocaine”.
Its studies are mostly in Peri-Implantitis · Pharyngitis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| A. Vogel | 10 open or running | phase 3since Jun 27, 2008 | Jun 27, 2008 | none ahead |
| Biointelligent Technology Systems SL | 10 open or running | no phasesince May 4, 2026 | May 4, 2026 | none ahead |
| Dexcel Pharma Technologies | 10 open or running | phase 2since Mar 2, 2010 | Mar 2, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2008First study: phase 3 study in PharyngitisNew to A. VogelA. Vogel · NCT00707902 · 154 enrolled · Switzerland
- Mar 2, 2010Dexcel Pharma Technologies's first study: phase 2 study in Peri-ImplantitisNew to Dexcel Pharma TechnologiesDexcel Pharma Technologies · NCT01079663 · 60 enrolled · Israel
- May 4, 2026Biointelligent Technology Systems SL's first study: no phase study in Tooth Extraction Site HealingNew to Biointelligent Technology Systems SLBiointelligent Technology Systems SL · NCT07611123 · 94 enrolled · Saudi Arabia
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cell membrane inhibitor”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07611123Tooth Extraction Site Healing · Saudi Arabia | – | Completed | Biointelligent Technology Systems SL | May 10, 2026 | 94 |
| NCT01079663Peri-Implantitis · Israel | 2 | Completed | Dexcel Pharma Technologies | Oct 2011 | 60 |
| NCT00707902Pharyngitis · Switzerland | 3 | Completed | A. Vogel | 154 |
How it is read
Names in the registry
- “chlorhexidine (CHX)”, 1 entry
- “Chlorhexidine 2.5 mg”, 1 entry
- “chlorhexidine/lidocaine”, 1 entry
Conditions, from the studies’ own filings
- Peri-Implantitis, 1 study
- Pharyngitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.